Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Nouveaux Pharma Limited

Manufacturer / licence-linked company · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Manufacturer / licence-linked company
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000003 2 linked products · source seen 10 Aug 2026 View source ↗
DSL 071 14 linked products · source seen 10 Aug 2026 View source ↗
DSL 073 21 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx37product presentations
G14generic molecules
DF7dosage-form groups
TA7therapeutic areas
PKR37current price records
REG33registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage68%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixNouveaux Pharma LimitedShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/nouveaux-pharma-limitedGenerated 10 Aug 2026Oncology & immunology18 · 49%Cardiovascular6 · 16%Hematology & thrombosis4 · 11%CNS & mental health4 · 11%Anti-infectives2 · 5%Endocrine & metabolic2 · 5%Anesthesia & critical care1 · 3%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioNouveaux Pharma LimitedDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/nouveaux-pharma-limitedGenerated 10 Aug 202637presentationsTablet14 · 38%Capsule9 · 24%Injection5 · 14%Infusion4 · 11%Drops2 · 5%Solution2 · 5%Other forms1 · 3%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionNouveaux Pharma LimitedCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/nouveaux-pharma-limitedGenerated 10 Aug 202625comparable productsBelow market median1 · 4%Near market median6 · 24%Above market median18 · 72%Company median price position+46.6%Lowest-price equivalents2Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsNouveaux Pharma LimitedCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/nouveaux-pharma-limitedGenerated 10 Aug 2026Pharmasol (Pvt) Ltd.6 shared43% overlapWerrick Pharmaceuticals5 shared36% overlapBio-Labs(Pvt) Ltd5 shared36% overlapScotmann Pharmaceuticals5 shared36% overlapNAVEGAL LABORATORIES5 shared36% overlapAJ Mirza Pharma Pvt Ltd5 shared36% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Oncology & immunology18 products · 49%
Cardiovascular6 products · 16%
Hematology & thrombosis4 products · 11%
CNS & mental health4 products · 11%
Anti-infectives2 products · 5%
Endocrine & metabolic2 products · 5%
Anesthesia & critical care1 products · 3%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antineoplastic medicines10 products · 27%
Immunosuppressants / immunomodulators8 products · 22%
Somatostatin analogues5 products · 14%
Iron chelators4 products · 11%
Antiepileptics4 products · 11%
Bone metabolism medicines2 products · 5%
Fluoroquinolone antibacterials1 products · 3%
Beta blockers1 products · 3%
Formulation footprint

Dosage forms

Tablet14 products
Capsule9 products
Injection5 products
Infusion4 products
Drops2 products
Solution2 products
Inhalation1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 TasignaNilotinib 7presentations 150 mg, 200 mg, 50 mg · Capsule #2 SandimmunCiclosporin 4presentations 100 mg, 100 mg/mL, 25 mg, 250 mg/5 mL (50 mg/mL) · Capsule, Solution, Infusion #3 TegralCarbamazepine 4presentations 100 mg, 100 mg/5 mL, 200 mg, 400 mg · Tablet, Solution #4 OleptissDeferasirox 3presentations 180 mg, 360 mg, 90 mg · Tablet #5 Sandostatin LAROctreotide 3presentations 10 mg, 20 mg, 30 mg · Injection #6 AfinitorEverolimus 2presentations 10 mg, 5 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median14% of comparable products
Near market median6within ±5% of median
Above market median1872% of comparable products
Lowest-price equivalents2ties included
Company median price position +46.6% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Tegral 400 mgCarbamazepine · Tablet · 50's PKR 11.36/tablet-36.9% vs market median Oleptiss 180 mgDeferasirox · Tablet · 30's PKR 323.20/tablet0.0% vs market median Oleptiss 360 mgDeferasirox · Tablet · 30's PKR 538.64/tablet0.0% vs market median Tegral 200 mgCarbamazepine · Tablet · 50's PKR 10.82/tablet+0.0% vs market median Zometa 4 mg/100 mLZoledronic acid · Solution for infusion · 1's PKR 33,275.75/vial/unit+3.9% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Pharmasol (Pvt) Ltd.251 products · 101 generics 6shared generics Werrick Pharmaceuticals249 products · 82 generics 5shared generics Bio-Labs(Pvt) Ltd234 products · 82 generics 5shared generics Scotmann Pharmaceuticals160 products · 57 generics 5shared generics NAVEGAL LABORATORIES110 products · 52 generics 5shared generics AJ Mirza Pharma Pvt Ltd109 products · 56 generics 5shared generics
Regulatory & price activity

Observed database signals

Registration numbers33
Price-history records41
Products with price history3
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date29 Jul 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

10 results
Intelligence filter: Drug classAntineoplastic medicines Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Femara Letrozole 2.5 mg Tablet 30's 021129 PKR 19,089.35 PKR 636.31/tablet 59% above median
Glivec Imatinib 400 mg Tablet 30's 033197 PKR 289,142.58 PKR 9,638.09/tablet 180% above median
Glivec Imatinib 100 mg Tablet 60's 033196 PKR 144,571.29 PKR 2,409.52/tablet 118% above median
Tasigna Nilotinib 150 mg Capsule 40's 072543 PKR 243,131.97 PKR 6,078.30/capsule 154% above median
Tasigna Nilotinib 200 mg Capsule 28's 052256 PKR 226,923.17 PKR 8,104.40/capsule 160% above median
Tasigna Nilotinib 50 mg Capsule 28's 105591 PKR 72,754.47 PKR 2,598.37/capsule Near median
Tasigna Nilotinib 150 mg Capsule 112's 072543 PKR 680,769.50 PKR 6,078.30/capsule 154% above median
Tasigna Nilotinib 200 mg Capsule 112's 052256 PKR 907,692.67 PKR 8,104.40/capsule 160% above median
Tasigna Nilotinib 50 mg Capsule 112's 105591 PKR 291,015.02 PKR 2,598.35/capsule Near median
Tasigna Nilotinib 150 mg Capsule 120's 072543 PKR 729,395.90 PKR 6,078.30/capsule 154% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.